Starling Oncology, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
STLN$4.00+10.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference · Filed or Furnished Herewith | ||||||
|---|---|---|---|---|---|---|
| Exhibit Number · Description · Form · File Number · Exhibit · Filing Date | ||||||
| 3.1 | Amended and Restated Certificate of Incorporation of The Oncology Institute, Inc. | 8-K | 001-39248 | 3.1 | November 18, 2021 | |
| 3.2 | Amended and Restated Bylaws of The Oncology Institute, Inc. | 8-K | 001-39248 | 3.2 | November 18, 2021 | |
| 3.3 | Certificate of Designation of Series A Common Stock Equivalent Convertible Preferred Stock | 8-K/A | 001-39248 | 3.3 | November 22, 2021 | |
| 3.4 | Certificate of Correction to Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock | 8-K | 001-39248 | 3.1 | March 25, 2025 | |
| 3.5 | Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock | 8-K | 001-39248 | 3.2 | March 25, 2025 | |
| 4.1 | Warrant Agreement, dated March 10, 2020, by and between DFP and Continental Stock Transfer & Trust Company, as warrant agent | 8-K | 001-39248 | 4.1 | March 13, 2020 | |
| 4.2 | Specimen Preferred Stock Certificate of The Oncology Institute, Inc. | 8-K/A | 001-39248 | 4.2 | November 22, 2021 | |
| 4.3 | Form of Secured Convertible Note | 8-K | 001-39248 | 4.1 | August 10, 2022 | |
| 4.4 | Form of Warrant | 8-K | 001-39248 | 4.2 | August 10, 2022 | |
| 4.5 | Form of pre-funded Warrant | 8-K | 001-39248 | 4.1 | March 25, 2025 | |
| 4.6 | Form of Common Warrant | 8-K | 001-39248 | 4.2 | March 25, 2025 | |
| 4.7 | Form of Deerfield Common Warrant | 8-K | 001-39248 | 4.3 | March 25, 2025 | |
| 31.1* | Certification Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of the Principal Executive Officer. | X | ||||
| 31.2* | Certification Pursuant to Rule 13a-14(a) under Securities Exchange Act of 1934 of the Principal Financial Officer. | X | ||||
| 32.1** | Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer. | X | ||||
| 32.2** | Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer | X | ||||
| 101.INS | Inline XBRL Instance Document | |||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||
| 104 | Cover Page Interactive Data File - (formatted as Inline XBRL and contained in Exhibit 101) | |||||
| * | Filed herewith. | |||||
| ** | Furnished herewith. | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.